Boniva Labeling Reflects Class Osteonecrosis, Musculoskeletal Pain Risk
Executive Summary
Labeling for Roche/GlaxoSmithKline's once-monthly osteoporosis agent Boniva reflects upcoming class labeling for osteonecrosis and musculoskeletal pain risk with oral bisphosphonates
You may also be interested in...
ASCO Adds Jaw Osteonecrosis Recommendations to Bisphosphonate Guideline
The American Society of Clinical Oncology's updated guideline for the use of bisphosphonates in patients with multiple myeloma warns of osteonecrosis of the jaw as a potential adverse effect, and agrees with the recommendations in revised FDA labels for the bone-strengthening drugs
ASCO Adds Jaw Osteonecrosis Recommendations to Bisphosphonate Guideline
The American Society of Clinical Oncology's updated guideline for the use of bisphosphonates in patients with multiple myeloma warns of osteonecrosis of the jaw as a potential adverse effect, and agrees with the recommendations in revised FDA labels for the bone-strengthening drugs
Boniva I.V. Once-Quarterly Safety Concerns Few, But Renal Tests Advised
Roche/GlaxoSmithKline's once-quarterly osteoporosis therapy Boniva injection does not present serious safety concerns compared with oral bisphosphonates, labeling for the I.V. formulation of the drug suggests